534 related articles for article (PubMed ID: 28202384)
1. Implementing take-home naloxone in an urban community pharmacy.
Akers JL; Hansen RN; Oftebro RD
J Am Pharm Assoc (2003); 2017; 57(2S):S161-S167. PubMed ID: 28202384
[TBL] [Abstract][Full Text] [Related]
2. Opioid overdose education and naloxone distribution: Development of the Veterans Health Administration's national program.
Oliva EM; Christopher MLD; Wells D; Bounthavong M; Harvey M; Himstreet J; Emmendorfer T; Valentino M; Franchi M; Goodman F; Trafton JA;
J Am Pharm Assoc (2003); 2017; 57(2S):S168-S179.e4. PubMed ID: 28292502
[TBL] [Abstract][Full Text] [Related]
3. The pharmacist role in the development and implementation of a naloxone prescription program in Alabama.
Wulz JL; Sung H; Dugan BD; Wensel TM; Lander R; Manzella B
J Am Pharm Assoc (2003); 2017; 57(2S):S141-S147. PubMed ID: 28209338
[TBL] [Abstract][Full Text] [Related]
4. Pharmacy-based statewide naloxone distribution: A novel "top-down, bottom-up" approach.
Morton KJ; Harrand B; Floyd CC; Schaefer C; Acosta J; Logan BC; Clark K
J Am Pharm Assoc (2003); 2017; 57(2S):S99-S106.e5. PubMed ID: 28292508
[TBL] [Abstract][Full Text] [Related]
5. Indian Health Service pharmacists engaged in opioid safety initiatives and expanding access to naloxone.
Duvivier H; Gustafson S; Greutman M; Jangchup T; Harden AK; Reinhard A; Warshany K
J Am Pharm Assoc (2003); 2017; 57(2S):S135-S140. PubMed ID: 28292501
[TBL] [Abstract][Full Text] [Related]
6. Implementing an overdose education and naloxone distribution program in a health system.
Devries J; Rafie S; Polston G
J Am Pharm Assoc (2003); 2017; 57(2S):S154-S160. PubMed ID: 28233681
[TBL] [Abstract][Full Text] [Related]
7. A nationwide pharmacy chain responds to the opioid epidemic.
Shafer E; Bergeron N; Smith-Ray R; Robson C; O'Koren R
J Am Pharm Assoc (2003); 2017; 57(2S):S123-S129. PubMed ID: 28163028
[TBL] [Abstract][Full Text] [Related]
8. The implementation of a naloxone rescue program in university students.
Panther SG; Bray BS; White JR
J Am Pharm Assoc (2003); 2017; 57(2S):S107-S112.e2. PubMed ID: 28063773
[TBL] [Abstract][Full Text] [Related]
9. What is known about community pharmacy supply of naloxone? A scoping review.
Nielsen S; Van Hout MC
Int J Drug Policy; 2016 Jun; 32():24-33. PubMed ID: 26949189
[TBL] [Abstract][Full Text] [Related]
10. Nonprescription naloxone and syringe sales in the midst of opioid overdose and hepatitis C virus epidemics: Massachusetts, 2015.
Stopka TJ; Donahue A; Hutcheson M; Green TC
J Am Pharm Assoc (2003); 2017; 57(2S):S34-S44. PubMed ID: 28189540
[TBL] [Abstract][Full Text] [Related]
11. Working together: Expanding the availability of naloxone for peer administration to prevent opioid overdose deaths in the Australian Capital Territory and beyond.
Lenton S; Dietze P; Olsen A; Wiggins N; McDonald D; Fowlie C
Drug Alcohol Rev; 2015 Jul; 34(4):404-11. PubMed ID: 25272281
[TBL] [Abstract][Full Text] [Related]
12. Strategies and policies to address the opioid epidemic: A case study of Ohio.
Penm J; MacKinnon NJ; Boone JM; Ciaccia A; McNamee C; Winstanley EL
J Am Pharm Assoc (2003); 2017; 57(2S):S148-S153. PubMed ID: 28189539
[TBL] [Abstract][Full Text] [Related]
13. The pharmacist's role in overdose: Using mapping technologies to analyze naloxone and pharmacy distribution.
Burrell A; Ethun L; Fawcett JA; Rickard-Aasen S; Williams K; Kearney SM; Pringle JL
J Am Pharm Assoc (2003); 2017; 57(2S):S73-S77.e1. PubMed ID: 28109629
[TBL] [Abstract][Full Text] [Related]
14. Accessing Take-Home Naloxone in British Columbia and the role of community pharmacies: Results from the analysis of administrative data.
Moustaqim-Barrette A; Papamihali K; Mamdani Z; Williams S; Buxton JA
PLoS One; 2020; 15(9):e0238618. PubMed ID: 32915834
[TBL] [Abstract][Full Text] [Related]
15. Awareness and Attitudes Toward Intranasal Naloxone Rescue for Opioid Overdose Prevention.
Kirane H; Ketteringham M; Bereket S; Dima R; Basta A; Mendoza S; Hansen H
J Subst Abuse Treat; 2016 Oct; 69():44-9. PubMed ID: 27568509
[TBL] [Abstract][Full Text] [Related]
16. Development and delivery of a pharmacist training program to increase naloxone access in Kentucky.
Palmer E; Hart S; Freeman PR
J Am Pharm Assoc (2003); 2017; 57(2S):S118-S122. PubMed ID: 28161300
[TBL] [Abstract][Full Text] [Related]
17. Attitudes and availability: A comparison of naloxone dispensing across chain and independent pharmacies in rural and urban areas in Alabama.
Sisson ML; McMahan KB; Chichester KR; Galbraith JW; Cropsey KL
Int J Drug Policy; 2019 Dec; 74():229-235. PubMed ID: 31698165
[TBL] [Abstract][Full Text] [Related]
18. Development of a targeted naloxone coprescribing program in a primary care practice.
Wilson CG; Rodriguez F; Carrington AC; Fagan EB
J Am Pharm Assoc (2003); 2017; 57(2S):S130-S134. PubMed ID: 28189537
[TBL] [Abstract][Full Text] [Related]
19. Development of a take-home naloxone program at an urban academic emergency department.
Eswaran V; Allen KC; Cruz DS; Lank PM; McCarthy DM; Kim HS
J Am Pharm Assoc (2003); 2020; 60(6):e324-e331. PubMed ID: 32690447
[TBL] [Abstract][Full Text] [Related]
20. The role of take-home naloxone in the epidemic of opioid overdose involving illicitly manufactured fentanyl and its analogs.
Kim HK; Connors NJ; Mazer-Amirshahi ME
Expert Opin Drug Saf; 2019 Jun; 18(6):465-475. PubMed ID: 31033357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
